<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HEPATITIS A VACCINE</span><br/>(hep'a-ti-tis)<br/><span class="topboxtradename">Havrix, </span><span class="topboxtradename">Vaqta<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">vaccine</span><br/><b>Prototype: </b>Hepatitis B vaccine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>720 EIU/0.5 mL, 1440 EIU/1 mL (Havrix); 25 U/0.5 mL, 50 U/1 mL (Vaqta)</p>
<h1><a name="action">Actions</a></h1>
<p>Anti-hepatitis A virus antibody titers following administration of hepatitis A vaccine (inactivated) are comparable to those
         observed after natural hepatitis A virus infection.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antibody levels are 50- to 300-fold higher with inactivated hepatitis A vaccine than with passive immunity with human immune
         globulin.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Active immunization against hepatitis A.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any component in vaccine, pregnancy (category C), children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hepatitis A Immunization</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 1 mL in deltoid muscle; booster dose (1 mL) at 612 mo after primary dose<br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> <i>118 y</i>, 2 doses of 0.5 mL in deltoid muscle given 1 mo apart; booster dose (0.5 mL) at 612 mo after primary doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give only in deltoid for adults and children older than 2 y. <small>DO NOT</small> give IV, SC, or intradermally.
         </li>
<li>Use vaccine as packaged without dilution.</li>
<li>Shake vial and syringe well before withdrawal and injection, respectively. Vaccine should be an opaque white suspension; discard
            if it looks otherwise.
         </li>
<li>Store at 2°8° C (36°47° F). Discard vaccine if it has been frozen.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Headache,</span> fatigue, fever, malaise, somnolence vertigo, insomnia, photophobia, convulsions, neuropathy, paresthesia. <span class="typehead">GI:</span> Anorexia, nausea, abdominal pain, diarrhea, dysgeusia, vomiting. <span class="typehead">Skin:</span> Pruritus, rash, urticaria, erythema multiforme, hyperhidrosis, <span class="speceff-life">angioedema</span> (rare). <span class="typehead">Other:</span> <span class="speceff-common">Soreness at injection site, pain, swelling, redness at injection site,</span> pharyngitis, lymphadenopathy. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 3 wk. <span class="typehead">Duration:</span> 13 y with single dose, 510 y with booster. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Do not administer during a febrile illness.</li>
<li>Assess for S&amp;S of anaphylaxis and have epinephrine available.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: Injection site soreness is common; most adverse reactions are mild and usually last less than 24 h. 						</li>
<li>Get booster injection within 612 mo if risk of exposure is still present.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>